RAVER : Prospective, observational SAFETY study of patients with Granulomatosis with polyangiitis(Wegener’s) or microscopic polyangiitis treated with rituximab
Principal Investigator: Patrick Nachman, MD
Sponsor: Genentech, Inc.
Age Range: 18 years of age and above
Status: Ongoing; not enrolling
Purpose: The purpose of this observational study is to collect information on individuals with granulomatosis with polyangiitis (GPA formerly known as Wegener’s granulomatosis) or microscopic polyangiitis (MPA) who are going to be treated with RITUXAN® (rituximab). Rituximab, in combination with glucocorticoids, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with GPA or MPA.
Study Procedures: The study will collect information about the participant’s treatment, his/her response to the treatment, side effects of treatment and other health information.
Participation: The study will last for 4 years. There will be a screening visit, a baseline visit and then a visit every 6 months. Each visit will last from 1 – 2 hours.
For more information, please contact: